Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Finished Goods (2023 - 2025)

Historic Finished Goods for Tg Therapeutics (TGTX) over the last 3 years, with Q3 2025 value amounting to $21.1 million.

  • Tg Therapeutics' Finished Goods rose 16485.81% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 16485.81%. This contributed to the annual value of $13.9 million for FY2024, which is 59724.86% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Finished Goods is $21.1 million, which was up 16485.81% from $21.8 million recorded in Q2 2025.
  • Tg Therapeutics' Finished Goods' 5-year high stood at $21.8 million during Q2 2025, with a 5-year trough of $52000.0 in Q1 2023.
  • Moreover, its 3-year median value for Finished Goods was $2.0 million (2023), whereas its average is $7.5 million.
  • The largest annual percentage gain for Tg Therapeutics' Finished Goods in the last 5 years was 355961.54% (2024), contrasted with its biggest fall of 14506.83% (2024).
  • Over the past 3 years, Tg Therapeutics' Finished Goods (Quarter) stood at $2.0 million in 2023, then surged by 597.25% to $13.9 million in 2024, then skyrocketed by 51.3% to $21.1 million in 2025.
  • Its last three reported values are $21.1 million in Q3 2025, $21.8 million for Q2 2025, and $10.7 million during Q1 2025.